Developer docs
API playgroundTry for free, no card

Search company profiles

IsoAid

Full company profile

uuid0009d44

Namestring
IsoAid
Legal namestring
IsoAid, LLC
Websiteurl
isoaid.com
Company typeenum
Private
Founded yearint
2000
Descriptiontext

IsoAid, LLC is a privately held U.S. medical device manufacturer founded in 2000 and headquartered in Port Richey, Florida (organized under Tennessee law). The company specializes in brachytherapy products for the treatment of localized cancers, with core offerings spanning radioactive seed manufacturing (Advantage I-125 and Advantage Pd-103), proprietary delivery accessories (Secure Strand textured strand, Advantage Seed Magazines with Dose Deflecting Collars), and the FDA-cleared IsoSphere bioabsorbable intracavity device for breast cancer. Its products serve healthcare providers performing prostate, ocular (eye plaque), and breast cancer brachytherapy procedures, and are listed in the joint AAPM/RPC registry and integrated into all major treatment planning software.

The company monetizes through direct hardware sales of seeds and accessories at quote-based, custom-prescribed-activity pricing, supplemented by service revenue from in-house loading, sterilization, and ADCL-calibrated assay. Its go-to-market combines enterprise field sales through territory managers with a minimum of 15 years of brachytherapy experience, a 24/7 customer service operation, an online client portal, and presence at three major oncology conferences (ASBrS, ABS, ASTRO). Two exclusive partnerships anchor the service layer: Dr. Melvin Astrahan / Eye Physics for ocular treatment planning and proprietary plaque technology, and Michael Sitter / Professional Dosimetry Services for prostate treatment planning.

IsoAid operates under ISO 13485 and MDSAP quality certifications with multi-jurisdiction regulatory clearances and IFU documentation in 15+ languages, supporting both U.S. and international sales. The company has no disclosed parent, no known institutional funding, and no publicly reported revenue or headcount, suggesting a founder- or management-owned specialty medical device business focused on niche oncology workflow integration rather than venture-scale growth.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersNew Port Richey, United States
HQ citystring
New Port Richey
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
brachytherapy seeds, radioactive seed implants, medical device manufacturing, cancer treatment devices, prostate brachytherapy
Industry3 codes
PRIMARYEUAKAIAD
Radiation Therapy Isotopes & Sources (Brachytherapy seeds, sealed sources for oncology)
Energy, Utilities & Environment/Nuclear Energy/Nuclear Materials, Radiation Services & Isotopes (Medical/Industrial)
SECONDARYEUAKAIAG
Radiation Processing & Sterilization Services (Medical device sterilization, food irradiation, materials modification)
Energy, Utilities & Environment/Nuclear Energy/Nuclear Materials, Radiation Services & Isotopes (Medical/Industrial)
SECONDARYEUAKAIAI
Sealed Source Manufacturing, Encapsulation & Recycling/Take-Back (Source lifecycle management)
Energy, Utilities & Environment/Nuclear Energy/Nuclear Materials, Radiation Services & Isotopes (Medical/Industrial)
NAICS code2 codes
  • Medical Equipment and Supplies Manufacturing3391
  • Surgical Appliance and Supplies Manufacturing339113
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Radiation Therapy Medical Devices
No data
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Medical Device Product Sales
TypeHardware Sales
Description

Manufacturing and marketing of brachytherapy products including seeds (Advantage I-125 and Pd-103), eye plaques, secure strands, seed magazines, and related accessories. Products sold at prescribed activity levels with in-house loading, sterilization, and assay services.

isoaid.com
2Service Revenue
TypeProfessional Services
Description

Full in-house loading, sterilization and assay services for prostate and eye plaque brachytherapy. Treatment planning services through exclusive partnerships. Order fulfillment with ADCL independent assay on all loaded plaques.

isoaid.com
3International Sales
TypeHardware Sales
Description

FDA-cleared products sold for diagnostic purposes in the U.S. and internationally, with IFU sheets available in multiple languages including Spanish, Dutch, French, German, Italian, and others.

isoaid.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Pricing details1 tier
1Quote-based pricing for medical devices
ModelOtherBilling cadencePay-as-you-go
Notes

Products are manufactured to customer specifications (prescribed activity levels). Pricing is handled through direct sales and online ordering system. Volume discounts on equipment may be available.

isoaid.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 4 records shown
1Advantage
Description

Product line including Advantage I-125 seeds (up to 12 mCi), Advantage Pd-103 seeds (up to 5 mCi), Advantage-Load, Advantage Secure Strand, and Advantage Seed Magazines.

isoaid.com
+3 more records
Core offering1 text field

IsoAid manufactures and supplies brachytherapy radioactive seeds and associated delivery systems used in the treatment of localized cancers, including prostate, ocular, and breast cancer. Its product line includes I-125 and Pd-103 seeds, stranded seed products (Secure Strand), pre-loaded seed magazines, eye plaque applicator kits, and radioactive seed localization (RSL) needles. The company sells these Class III medical devices to healthcare providers, radiation oncologists, and treatment centers.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • 78% more resistant to movement than standard strands
+2 more records
Product overview1 text field

IsoAid is a premier medical device company manufacturing and marketing full-service Brachytherapy products for treatment of localized cancers. The core product portfolio consists of Advantage I-125 and Advantage Pd-103 radioactive seeds used for prostate, ocular, and breast cancer brachytherapy. Supporting products include Secure Strand (a textured strand exclusive to IsoAid with superior seed retention), Advantage Seed Magazines (shielded cartridges with Dose Deflecting Collars for Mick applicators), Advantage Eye Plaque Applicator Kits, and IsoSphere (a new FDA-cleared bioabsorbable brachytherapy device for breast cancer). The company also provides Radioactive Seed Localization (RSL) needles for diagnostic tumor localization. All products are manufactured under ISO 13485 and MDSAP certifications with in-house loading, sterilization, and assay services.

Product and service8 records
1Advantage I-125 Seed
CategoryBrachytherapy Seeds
Description

Iodine-125 (I-125) radioactive brachytherapy seed used by radiation oncologists and urologists for permanent interstitial implantation in low-dose-rate (LDR) brachytherapy treatment of localized prostate cancer and other malignancies.

2Advantage Pd-103 Seed
3Secure Strand
4Advantage Seed Magazines
5IsoSphere
6Radioactive Seed Localization (RSL) Needles
7Advantage Eye Plaque Applicator Kit
8Advantage-Load Custom Loaded Seeds
Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
1Dr. Melvin Astrahan, PhD / Eye Physics, LLC
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Exclusive partnership providing access to COMS plaques and over 50 models of Eye Physics collimated plaques, along with proprietary Plaque Simulator advanced 3D planning software. Planning services also provided by Eye Physics for eye plaque brachytherapy treatments.

isoaid.com
2Michael Sitter, RT(T) / Professional Dosimetry Services
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Exclusive partnership for Prostate Brachytherapy treatment planning services through Michael Sitter at Professional Dosimetry Services (PDS Seattle). Services include feedback from industry experts for treatment planning.

isoaid.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

IsoRay is a direct competitor manufacturing brachytherapy seeds, particularly known for Cesium-131 isotopes used in prostate, brain, and other cancer treatments. They compete head-to-head with IsoAid's I-125 and Pd-103 products in the same clinical indications and hospital customer base.

TypeDirect peer
Description

Theragenics is a direct competitor manufacturing Pd-103 and I-125 brachytherapy seeds (TheraSeed and TheraStrand) and has historically been one of the largest players in the prostate brachytherapy seed market alongside IsoAid. They also sell to healthcare providers with similar treatment planning and loading services.

TypeDirect peer
Description

Eckert & Ziegler's BEBIG division manufactures I-125, Pd-103, and other brachytherapy seeds (e.g., IsoSeed, Intersource) used in prostate, eye plaque, and other cancer treatments. They are one of the largest global brachytherapy product manufacturers, directly competing with IsoAid's product portfolio.

TypeBroad incumbent
Description

Elekta is a global leader in radiation therapy and radiosurgery, offering brachytherapy afterloaders (Flexitron) and treatment planning software used alongside brachytherapy seeds. As a broad incumbent in radiation oncology, Elekta competes with IsoAid by offering the complete ecosystem of hardware, software, and service that hospitals purchase.

TypeBroad incumbent
Description

Siemens Healthineers (which acquired Varian Medical Systems) is a broad incumbent in radiation oncology, offering linear accelerators, brachytherapy afterloaders, and treatment planning systems. They compete with IsoAid in the broader radiation oncology ecosystem and partner with seed manufacturers.

TypeBroad incumbent
Description

BD acquired C.R. Bard, which had a significant brachytherapy product portfolio including I-125 seeds and other oncology products. As a much larger medical device conglomerate, BD represents a broad incumbent competitor with greater R&D and distribution resources.

TypeEmerging player
Description

iCAD's Xoft division offers electronic brachytherapy (eBx) systems for breast, skin, and other cancer treatments, providing a radiation-free alternative to radioactive seed brachytherapy. They compete with IsoAid's IsoSphere in the breast IORT market with a different technology approach.

TypeEmerging player
Description

Sensus Healthcare provides superficial radiation therapy (SRT) systems primarily for skin cancer and keloid treatment. While not a direct seed competitor, they represent an emerging player in the office-based radiation therapy space, intersecting with some of IsoAid's clinical customer base in radiation oncology.

9Carl Zeiss Meditec
TypeOthers
Description

Carl Zeiss Meditec is a medical technology company that provides ophthalmic devices and radiation therapy products, including eye plaque applicators used in ocular cancer treatment. They are a thematically related company in the broader radiation oncology and ocular oncology ecosystem where IsoAid operates.

10Best Medical International
TypeDirect peer
Description

Best Medical International manufactures brachytherapy products including I-125 and Pd-103 seeds, as well as eye plaque applicators and other radiation therapy accessories. They are a direct competitor to IsoAid across multiple product lines, particularly in the seed and applicator categories.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

IsoAid

Radiation Therapy Medical Devicesisoaid.com

What IsoAid does

IsoAid, LLC is a privately held U.S. medical device manufacturer founded in 2000 and headquartered in Port Richey, Florida (organized under Tennessee law). The company specializes in brachytherapy products for the treatment of localized cancers, with core offerings spanning radioactive seed manufacturing (Advantage I-125 and Advantage Pd-103), proprietary delivery accessories (Secure Strand textured strand, Advantage Seed Magazines with Dose Deflecting Collars), and the FDA-cleared IsoSphere bioabsorbable intracavity device for breast cancer. Its products serve healthcare providers performing prostate, ocular (eye plaque), and breast cancer brachytherapy procedures, and are listed in the joint AAPM/RPC registry and integrated into all major treatment planning software.

The company monetizes through direct hardware sales of seeds and accessories at quote-based, custom-prescribed-activity pricing, supplemented by service revenue from in-house loading, sterilization, and ADCL-calibrated assay. Its go-to-market combines enterprise field sales through territory managers with a minimum of 15 years of brachytherapy experience, a 24/7 customer service operation, an online client portal, and presence at three major oncology conferences (ASBrS, ABS, ASTRO). Two exclusive partnerships anchor the service layer: Dr. Melvin Astrahan / Eye Physics for ocular treatment planning and proprietary plaque technology, and Michael Sitter / Professional Dosimetry Services for prostate treatment planning.

IsoAid operates under ISO 13485 and MDSAP quality certifications with multi-jurisdiction regulatory clearances and IFU documentation in 15+ languages, supporting both U.S. and international sales. The company has no disclosed parent, no known institutional funding, and no publicly reported revenue or headcount, suggesting a founder- or management-owned specialty medical device business focused on niche oncology workflow integration rather than venture-scale growth.

IsoAid firmographics

Firmographics
Name
IsoAid
Legal name
IsoAid, LLC
Website
https://isoaid.com
Company type
Private
Founded year
2000
Operating status
Operating
Headcount range
11–50 employees
Ownership category
akta.pro rank

IsoAid industry classification

Industry
Product category
Radiation Therapy Medical Devices
NAICS
Medical Equipment and Supplies Manufacturing (3391), Surgical Appliance and Supplies Manufacturing (339113)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYEUAKAIAD
Radiation Therapy Isotopes & Sources (Brachytherapy seeds, sealed sources for oncology)
Energy, Utilities & Environment/Nuclear Energy/Nuclear Materials, Radiation Services & Isotopes (Medical/Industrial)
SECONDARYEUAKAIAG
Radiation Processing & Sterilization Services (Medical device sterilization, food irradiation, materials modification)
Energy, Utilities & Environment/Nuclear Energy/Nuclear Materials, Radiation Services & Isotopes (Medical/Industrial)
SECONDARYEUAKAIAI
Sealed Source Manufacturing, Encapsulation & Recycling/Take-Back (Source lifecycle management)
Energy, Utilities & Environment/Nuclear Energy/Nuclear Materials, Radiation Services & Isotopes (Medical/Industrial)

Keywords

  • Brachytherapy seeds
  • Radioactive seed implants
  • Medical device manufacturing
  • Cancer treatment devices
  • Prostate brachytherapy

Where IsoAid is headquartered

Location

Headquarters

HQ city
New Port Richey
HQ country
United States
HQ region
North America

Offices1 record

Markets served

IsoAid business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing

Revenue model

  1. Medical Device Product Sales: Manufacturing and marketing of brachytherapy products including seeds (Advantage I-125 and Pd-103), eye plaques, secure strands, seed magazines, and related accessories. Products sold at prescribed activity levels with in-house loading, sterilization, and assay services.
  2. Service Revenue: Full in-house loading, sterilization and assay services for prostate and eye plaque brachytherapy. Treatment planning services through exclusive partnerships. Order fulfillment with ADCL independent assay on all loaded plaques.
  3. International Sales: FDA-cleared products sold for diagnostic purposes in the U.S. and internationally, with IFU sheets available in multiple languages including Spanish, Dutch, French, German, Italian, and others.

Pricing tiers

ModelBillingPrice
OtherPay-as-you-goQuote-based pricing for medical devices

Go-to-market motion2 records

Distribution channels3 records

Marketing channels4 records

IsoAid product offering

Product offering

Core offering

IsoAid manufactures and supplies brachytherapy radioactive seeds and associated delivery systems used in the treatment of localized cancers, including prostate, ocular, and breast cancer. Its product line includes I-125 and Pd-103 seeds, stranded seed products (Secure Strand), pre-loaded seed magazines, eye plaque applicator kits, and radioactive seed localization (RSL) needles. The company sells these Class III medical devices to healthcare providers, radiation oncologists, and treatment centers.

Product overview

IsoAid is a premier medical device company manufacturing and marketing full-service Brachytherapy products for treatment of localized cancers. The core product portfolio consists of Advantage I-125 and Advantage Pd-103 radioactive seeds used for prostate, ocular, and breast cancer brachytherapy. Supporting products include Secure Strand (a textured strand exclusive to IsoAid with superior seed retention), Advantage Seed Magazines (shielded cartridges with Dose Deflecting Collars for Mick applicators), Advantage Eye Plaque Applicator Kits, and IsoSphere (a new FDA-cleared bioabsorbable brachytherapy device for breast cancer). The company also provides Radioactive Seed Localization (RSL) needles for diagnostic tumor localization. All products are manufactured under ISO 13485 and MDSAP certifications with in-house loading, sterilization, and assay services.

Differentiator

Problem solved

Functional benefit

Brands

  • Advantage: Product line including Advantage I-125 seeds (up to 12 mCi), Advantage Pd-103 seeds (up to 5 mCi), Advantage-Load, Advantage Secure Strand, and Advantage Seed Magazines.
  • IsoSphere
  • Secure Strand
  • COMS Plaques

Products and services

  • Advantage I-125 Seed Iodine-125 (I-125) radioactive brachytherapy seed used by radiation oncologists and urologists for permanent interstitial implantation in low-dose-rate (LDR) brachytherapy treatment of localized prostate cancer and other malignancies.
  • Advantage Pd-103 Seed
  • Secure Strand
  • Advantage Seed Magazines
  • IsoSphere
  • Radioactive Seed Localization (RSL) Needles
  • Advantage Eye Plaque Applicator Kit
  • Advantage-Load Custom Loaded Seeds

Quantifiable outcome

  • 78% more resistant to movement than standard strands
  • +2 more outcomes

Companies that use IsoAid

Customer profile

Segments4 records

IsoAid technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature6 records

IsoAid partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • Dr. Melvin Astrahan, PhD / Eye Physics, LLCcoreStrategic or Co-development PartnerExclusive partnership providing access to COMS plaques and over 50 models of Eye Physics collimated plaques, along with proprietary Plaque Simulator advanced 3D planning software. Planning services also provided by Eye Physics for eye plaque brachytherapy treatments.
  • Michael Sitter, RT(T) / Professional Dosimetry ServicescoreStrategic or Co-development PartnerExclusive partnership for Prostate Brachytherapy treatment planning services through Michael Sitter at Professional Dosimetry Services (PDS Seattle). Services include feedback from industry experts for treatment planning.

Scale indicators3 records

Recent moves6 records

Expansion highlights6 records

IsoAid competitors and assessment

Company assessment

Direct peers

  • IsoRay Medical: IsoRay is a direct competitor manufacturing brachytherapy seeds, particularly known for Cesium-131 isotopes used in prostate, brain, and other cancer treatments. They compete head-to-head with IsoAid's I-125 and Pd-103 products in the same clinical indications and hospital customer base.
  • Theragenics (now part of BrachySciences/GT Medical Technologies): Theragenics is a direct competitor manufacturing Pd-103 and I-125 brachytherapy seeds (TheraSeed and TheraStrand) and has historically been one of the largest players in the prostate brachytherapy seed market alongside IsoAid. They also sell to healthcare providers with similar treatment planning and loading services.
  • Eckert & Ziegler (BEBIG division): Eckert & Ziegler's BEBIG division manufactures I-125, Pd-103, and other brachytherapy seeds (e.g., IsoSeed, Intersource) used in prostate, eye plaque, and other cancer treatments. They are one of the largest global brachytherapy product manufacturers, directly competing with IsoAid's product portfolio.
  • Best Medical International: Best Medical International manufactures brachytherapy products including I-125 and Pd-103 seeds, as well as eye plaque applicators and other radiation therapy accessories. They are a direct competitor to IsoAid across multiple product lines, particularly in the seed and applicator categories.

Broad incumbents

  • Elekta: Elekta is a global leader in radiation therapy and radiosurgery, offering brachytherapy afterloaders (Flexitron) and treatment planning software used alongside brachytherapy seeds. As a broad incumbent in radiation oncology, Elekta competes with IsoAid by offering the complete ecosystem of hardware, software, and service that hospitals purchase.
  • Siemens Healthineers (Varian): Siemens Healthineers (which acquired Varian Medical Systems) is a broad incumbent in radiation oncology, offering linear accelerators, brachytherapy afterloaders, and treatment planning systems. They compete with IsoAid in the broader radiation oncology ecosystem and partner with seed manufacturers.
  • Becton Dickinson (BD): BD acquired C.R. Bard, which had a significant brachytherapy product portfolio including I-125 seeds and other oncology products. As a much larger medical device conglomerate, BD represents a broad incumbent competitor with greater R&D and distribution resources.

Emerging players

  • iCAD (Xoft): iCAD's Xoft division offers electronic brachytherapy (eBx) systems for breast, skin, and other cancer treatments, providing a radiation-free alternative to radioactive seed brachytherapy. They compete with IsoAid's IsoSphere in the breast IORT market with a different technology approach.
  • Sensus Healthcare: Sensus Healthcare provides superficial radiation therapy (SRT) systems primarily for skin cancer and keloid treatment. While not a direct seed competitor, they represent an emerging player in the office-based radiation therapy space, intersecting with some of IsoAid's clinical customer base in radiation oncology.

Others

  • Carl Zeiss Meditec: Carl Zeiss Meditec is a medical technology company that provides ophthalmic devices and radiation therapy products, including eye plaque applicators used in ocular cancer treatment. They are a thematically related company in the broader radiation oncology and ocular oncology ecosystem where IsoAid operates.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

IsoAid compliance and trust

Trust signal

Compliance3 records

IsoAid financial estimates

Financial estimate

Revenue estimate

Valuation estimate

IsoAid leadership team

Management profile

Number of profiles

IsoAid funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

IsoAid M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about IsoAid

What does IsoAid do?

IsoAid manufactures and supplies brachytherapy radioactive seeds and associated delivery systems used in the treatment of localized cancers, including prostate, ocular, and breast cancer. Its product line includes I-125 and Pd-103 seeds, stranded seed products (Secure Strand), pre-loaded seed magazines, eye plaque applicator kits, and radioactive seed localization (RSL) needles. The company sells these Class III medical devices to healthcare providers, radiation oncologists, and treatment centers.

Is IsoAid a public or private company?

IsoAid is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was IsoAid founded?

IsoAid was founded in 2000. It employs 11 to 50 people.

Where is IsoAid based?

IsoAid is headquartered in New Port Richey, United States, in the North America region.

How does IsoAid make money?

Three revenue lines are on record. Medical Device Product Sales are the primary driver. The others are service Revenue and international Sales.

Who are IsoAid's main competitors?

Direct peers on record are IsoRay Medical, Theragenics (now part of BrachySciences/GT Medical Technologies), Eckert & Ziegler (BEBIG division) and Best Medical International. Broad incumbents are Elekta, Siemens Healthineers (Varian) and Becton Dickinson (BD). Emerging players are iCAD (Xoft) and Sensus Healthcare. Carl Zeiss Meditec is listed as an others.

Does IsoAid have an API?

No public API is recorded for IsoAid.

What industry is IsoAid in?

IsoAid's product category is Radiation Therapy Medical Devices. Its primary akta.pro industry code is EUAKAIAD, Radiation Therapy Isotopes & Sources (Brachytherapy seeds, sealed sources for oncology), with a secondary code of EUAKAIAG, Radiation Processing & Sterilization Services (Medical device sterilization, food irradiation, materials modification). Its NAICS code is 3391 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales